Latanoprost/Timolol Kent Pharma Uk (Timolol Maleate, Latanoprost)

Latanoprost/Timolol is indicated for conditions affecting intra‑ocular pressure within the glaucoma and ocular hypertension disease family.

• Open‑angle glaucoma: reduces intra‑ocular pressure to prevent optic‑nerve damage and visual field loss.
• Ocular hypertension: lowers pressure to reduce the risk of progression to glaucoma.
• Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.

• Latanoprost, a prostaglandin F2α analogue, increases uveoscleral outflow of aqueous humor, while timolol maleate, a non‑selective beta‑adrenergic antagonist, decreases aqueous humor production by blocking β1 and β2 receptors in the ciliary body. The combined actions result in a net reduction of intra‑ocular pressure.

Common Side Effects

• Eye irritation or burning sensation after instillation.
• Conjunctival hyperemia (redness of the eye).
• Transient blurred vision.
• Darkening of the iris or peri‑ocular skin.
• Increased eyelash growth.

Serious or Rare Side Effects

• Severe allergic reaction with swelling, itching, or rash.
• Uveitis or iritis presenting as eye pain and photophobia.
• Persistent ocular pain or vision loss.
• Systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm.
• Acute angle‑closure glaucoma precipitated by pupil dilation.

Before using Latanoprost/Timolol, consider the following precautions:

• Cardiovascular assessment: monitor heart rate and blood pressure in patients with cardiac disease.
• Respiratory caution: avoid in patients with asthma or chronic obstructive pulmonary disease.
• Diabetes monitoring: beta‑blockade may mask hypoglycaemia symptoms.
• Contact lens use: advise removal of lenses before and for several hours after instillation.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk.
• Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost/Timolol may interact with other medicines as follows:

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers: additive bradycardia or hypotension.
• Other ocular beta‑blocker drops: excessive intra‑ocular pressure reduction.
• Additional prostaglandin analog eye drops: increased risk of ocular irritation.

Moderate Interactions (Monitor Closely)

• Inhaled beta‑agonists (e.g., albuterol): may reduce bronchodilator efficacy.
• Calcium channel blockers: possible additive cardiovascular effects.
• Anticholinergic eye drops: may alter pupil response.
• NSAID eye preparations: potential for increased ocular inflammation.